Foreword
Leonard Girnita is an Associate Professor of Pathology in the Department of Oncology/Pathology at the Karolinska Institute. He is also a specialist in pathology at St Eriks Eye Hospital in Stockholm. His research career has entirely been in cancer research, including translational and basic research, support of clinical and pre-clinical studies on breast cancer, melanoma, uveal melanoma and soft-tissue sarcomas and a drug discovery program on IGF-1R in cancer. His specific interests include receptor-mediated cell signaling in cancer with focus on the cross-talk between different classes of receptors. Dr Girnita is the principal investigator on several ongoing studies targeting cell signalling mechanisms in cancer treatment. He is an Associate Editor and/or reviewer for several journals within the fields of cancer research and endocrinology. He is an active member of the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the Growth Hormone and IGF Society and the European Ophthalmic Pathology Society (EOPS).
elcome to this issue of European Oncology. Like the successful previous editions, this publication endeavours to provide the reader with salient and informative topics, featuring a series of articles that discuss and review many important issues relevant to oncologists and physicians throughout Europe, and indeed globally.
W
In the ‘Current Issues’ section, Denis Talbot et al. discuss survivin, which has been shown to be upregulated in many cancer types while being minimally expressed in normal adult tissue. These authors review the roles of survivin in mitosis and apoptosis, its regulation and the pre-clinical and clinical data on the emerging survivin-directed therapies.
Agnes Czimbalmos and Andrew Bottomley review the application of patient-reported outcomes in clinical care and consider its benefits, challenges and potential improvements in the ‘Supportive Oncology’ section. They address major concerns that, despite the wide use of information-gathering questionnaires and their promising results, it is still a challenge to predict the full value of these measures in clinical care.
Christian Jackisch et al. discuss the evolution of the 21-gene assay Oncotype DX® from an experimental assay to an instrument assisting in risk prediction and optimisation of treatment decision-making in early breast cancer.
In the ‘Colorectal Cancer’ section, Matteo Landriscina et al. discuss the role of the thrombin receptor activating peptide 1 (TRAP1)/heat shock protein 90 (HSP90) anti-apoptotic pathway, which is involved in drug resistance and may became a novel potential molecular target to improve the efficacy of drug therapies in human colorectal carcinoma.
Mustafa Ozturk and Fikret Arpaci review the comparative efficacy of reduced or standard doses of lenograstim for peripheral blood stem cell mobilisation and transplantation in the ‘Haematological Cancer’ section. Jesús San-Miguel states that the outcome for myeloma patients has significantly improved over the last decade, and he goes on to discuss therapeutic approaches in the newly diagnosed myeloma patient.
John Bean et al. discuss the Imaging Programme of the European Organisation for Research and Treatment of Cancer, which is dedicated to improving the quality and consistency of evaluation of cancer treatment within its clinical trials through the incorporation of imaging technologies used for treatment definition for radiotherapy, staging, prediction and evaluation of response or pathology.
European Oncology would like to thank everyone involved for successfully providing these and other interesting and informative expert discussions on a variety of oncological topics that warrant our debate, time and attention. We would like to thank the organisations, media partners and Editorial Board for their continued support, and also extend our gratitude to the individual authors for their time and effort, which has resulted in a selection of excellent articles. We trust you will find this edition an informative and enjoyable read. n
8
© TOUCH BRIEFINGS 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100